Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib

Metastatic human pancreatic cancer cells (the SW1990 line) that are resistant to the EGFR-targeting tyrosine kinase inhibitor drugs (TKI) erlotinib and gefitinib were treated with 1,3,4-O-Bu(3)ManNAc, a “metabolic glycoengineering” drug candidate that increased sialylation by ∼12-fold. Consistent wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Mohit P., Tan, Elaine, Saeui, Christopher T., Bovonratwet, Patawut, Liu, Lingshu, Bhattacharya, Rahul, Yarema, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753412/
https://www.ncbi.nlm.nih.gov/pubmed/25690786
http://dx.doi.org/10.1016/j.bmcl.2015.01.060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753412/
https://www.ncbi.nlm.nih.gov/pubmed/25690786
http://dx.doi.org/10.1016/j.bmcl.2015.01.060

Ejemplares similares